Provided by Tiger Trade Technology Pte. Ltd.

NEUROGENE INC

39.64
+1.012.61%
Pre-market: 39.00-0.6400-1.61%08:15 EDT
Volume:439.10K
Turnover:17.35M
Market Cap:793.25M
PE:-7.86
High:40.82
Open:38.64
Low:37.50
Close:38.63
52wk High:43.66
52wk Low:15.93
Shares:20.01M
Float Shares:11.34M
Volume Ratio:2.12
T/O Rate:3.87%
Dividend:- -
Dividend Rate:- -
EPS(TTM):-5.0440
EPS(LYR):-4.2400
ROE:-45.32%
ROA:-27.97%
PB:3.65
PE(LYR):-9.35

Loading ...

Press Release: Neurogene Reports First Quarter 2026 Financial Results and Highlights Recent Updates

Dow Jones
·
May 13

Neurogene says NGN-401 Rett trial shows milestone gains up to 24 months

Reuters
·
May 12

Neurogene President, CFO Christine Mikail Cvijic sells USD 300,821 common shares

Reuters
·
May 08

BRIEF-Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

Reuters
·
May 07

Neurogene grants 122,565 inducement stock options to two new employees

Reuters
·
May 07

Neurogene Inc expected to post a loss of $1.30 a share - Earnings Preview

Reuters
·
May 05

Guggenheim Initiates Neurogene at Buy With $69 Price Target

MT Newswires Live
·
Apr 28

Neurogene highlights NGN-401 Phase 1/2 Rett syndrome data ahead of ASGCT poster

Reuters
·
Apr 28

BRIEF-Neurogene Appoints Christy Shafer As Chief Commercial Officer And Christine Mikail, J.D., To Board Of Directors

Reuters
·
Apr 20

Neurogene names Christy Shafer chief commercial officer

Reuters
·
Apr 20

Neurogene Appoints Christy Shafer as Chief Commercial Officer and Christine Mikail, J.d., to Board of Directors

THOMSON REUTERS
·
Apr 20

Companies Like Neurogene (NASDAQ:NGNE) Are In A Position To Invest In Growth

Simply Wall St.
·
Apr 20

Neurogene announces annual shareholder meeting

Reuters
·
Apr 17

Neurogene grants inducement stock options for 69,140 shares to new hires

Reuters
·
Apr 09

Neurogene Announces Inducement Grants Under Nasdaq Listing Rule 5635(C)(4)

THOMSON REUTERS
·
Apr 09

Analysts Offer Insights on Healthcare Companies: Neurogene (NGNE), Alzamend Neuro (ALZN) and Cardiol Therapeutics (CRDL)

TIPRANKS
·
Apr 08

Neurogene Is Maintained at Buy by Canaccord Genuity

Dow Jones
·
Apr 06

Neurogene price target lowered to $180 from $200 at Canaccord

TIPRANKS
·
Apr 06

Canaccord Genuity Remains a Buy on Neurogene (NGNE)

TIPRANKS
·
Apr 06

Neurogene (NGNE) Receives a Buy from LifeSci Capital

TIPRANKS
·
Mar 28